Relevant to MS, HDAC inhibitors have generally been demonstrated to have anti-inflammatory effects including increased Foxp3 expression and increased numbers of Foxp3+ Treg cells [40]. This evidence concerns the gene FOXP3 and myeloid sarcoma.